Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study.
Mult Scler J Exp Transl Clin. 2021 Jan 31;7(1):2055217320973049. doi: 10.1177/2055217320973049. eCollection 2021 Jan-Mar.
Mult Scler J Exp Transl Clin. 2021.
PMID: 33796328
Free PMC article.